<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01292655</url>
  </required_header>
  <id_info>
    <org_study_id>CA216-001</org_study_id>
    <nct_id>NCT01292655</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>Phase 1 Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BMS-906024 in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify a safe and tolerable dose of BMS-906024 in subjects
      with advanced or metastatic solid tumors who no longer respond to or have relapsed from
      standard therapies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 3, 2011</start_date>
  <completion_date type="Actual">June 22, 2017</completion_date>
  <primary_completion_date type="Actual">June 22, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with adverse events as a measure of safety and tolerability</measure>
    <time_frame>Weekly assessments until study discontinuation due to disease progression or unacceptable adverse event as well as an assessment 30 day after treatment discontinuation with an average time on study expected to be &lt;1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor assessments using response evaluation criteria in solid tumors (RECIST) v1.1</measure>
    <time_frame>Tumor assessments at least every 8 weeks during treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD changes from baseline in the expression of Notch pathway-related genes in surrogate tissues (peripheral blood cells) and tumor biopsies</measure>
    <time_frame>PD changes from baseline during the first 4-5 weeks of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters for BMS-906024 and its metabolite BMS-911557, maximum observed concentration (Cmax)</measure>
    <time_frame>PK at multiple time points during the first 8 weeks of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters for BMS-906024 and its metabolite BMS-911557, minimum observed concentration (Cmin)</measure>
    <time_frame>PK at multiple time points during the first 8 weeks of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters for BMS-906024 and its metabolite BMS-911557, time to reach maximum observed concentration (Tmax)</measure>
    <time_frame>PK at multiple time points during the first 8 weeks of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters for BMS-906024 and its metabolite BMS-911557, terminal phase elimination half-life (T-Half)</measure>
    <time_frame>PK at multiple time points during the first 8 weeks of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters for BMS-906024 and its metabolite BMS-911557, accumulation index (AI)</measure>
    <time_frame>PK at multiple time points during the first 8 weeks of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters for BMS-906024 and its metabolite BMS-911557, area under the concentration-time curve (AUC)</measure>
    <time_frame>PK at multiple time points during the first 8 weeks of dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A1 (Escalation): BMS-906024</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-906024 solution intravenously as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A2 (Expansion): BMS-906024</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-906024 solution intravenously as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B1 (Escalation): BMS-906024</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-906024 solution intravenously as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B2 (Expansion): BMS-906024</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-906024 solution intravenously as specified</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-906024</intervention_name>
    <arm_group_label>Arm A1 (Escalation): BMS-906024</arm_group_label>
    <arm_group_label>Arm A2 (Expansion): BMS-906024</arm_group_label>
    <arm_group_label>Arm B1 (Escalation): BMS-906024</arm_group_label>
    <arm_group_label>Arm B2 (Expansion): BMS-906024</arm_group_label>
    <other_name>BMS-906024 (Notch inhibitor)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com.

        Inclusion Criteria:

          -  Subjects with advanced or metastatic solid tumors (non-hematologic refractory to or
             relapsed from standard therapies or for which there is no known effective treatment
             during dose escalation

          -  Subjects with squamous non-small cell lung cancer and triple-negative breast cancer or
             other solid tumor types for which Notch activation has been demonstrated (such as
             pancreatic, ovarian and melanoma) during dose expansion

          -  Biopsy accessible tumor (may be waived under certain circumstances)

          -  Life expectancy of at least 3 months

          -  Eastern Cooperative Oncology Group (ECOG) 0-1

          -  Adequate organ and bone marrow function

        Exclusion Criteria:

          -  Infection

          -  Elevated triglycerides

          -  Gastrointestinal (GI) disease with increased risk of diarrhea [e.g. inflammatory bowel
             disease (IBD)]

          -  Taking medications known to increase risk of Torsades De Pointes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anthony El-Khoueiry, Md</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital Research Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2011</study_first_submitted>
  <study_first_submitted_qc>February 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2011</study_first_posted>
  <last_update_submitted>October 16, 2017</last_update_submitted>
  <last_update_submitted_qc>October 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

